Medidata Stock Analysis, Valuation (NASDAQ:MDSO)

Add to My Stocks
$63.76 $1.26 (1.94%) MDSO stock closing price Mar 23, 2018 (Closing)
Watch Robo Advisor Video of MDSO Stock Analysis
Updated on : Mar 23, 2018
previous close
MDSO 65 (0%)
S&P 500 2643.7 (0%)
Closing Price On: Mar 22, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Information Systems
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt/Equity Ratio:
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
Recent Growth
Operating Margins
Net Margins
FCF Margin
High Debt Burden
PE Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Medidata Stock Analysis

70 5 2

Watch the robo advisor video of Medidata stock analysis on Amigobulls. Our MDSO analysis video highlights revenue and profit trends along with other important metrics such as valuation to find what makes the stock attractive.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

Medidata Solutions Inc Stock Rating 3.5/5

Amigobulls MDSO stock analysis takes into account various financial ratios like relative valuation, Medidata revenue, growth and return on equity based on latest quarter 2017 Q4 financial statements. We also check Medidata dividend performance. We compare Medidata valuation with its sector peers to gauge relative attractiveness of MDSO stock. Medidata stock rating is our opinion about the business fundamentals of the company.

Should you buy MDSO stock?

  • The Year Over Year (YoY) revenue growth for Medidata was 13.5% in 2017 Q4.
  • Medidata's average operating margin of 11.8% was exceptional.
  • LTM Net margins were good at 8.1% for Medidata.
  • Medidata generates a high return on invested capital of 15.3%.
  • The LTM ROE of 10% for Medidata is attractive.
  • The company has a good Free Cash Flow (FCF) margin of 11.4%.

Should you sell MDSO stock?

  • With a debt/equity ratio of  0.76, Medidata is highly leveraged in comparison to Medical peers.
  • MDSO stock is trading at a PE ratio of 78.8, which is worse than the industry average multiple of 24.

Comments on this video and Medidata stock

Investors can use Amigobulls Medidata stock analysis as a tool to arrive at accurate conclusions regarding financial health of the company and its valuation. Fundamentals of a company give detailed information which helps in making invesment decisions.

Medidata revenue growth and profit or net income are the main underlying forces which could detremine the direction of the share price. Investors could make use of MDSO technical analysis to check whether the fundamental story is reflected in the market sentiment.